Navigation Links
Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million
Date:12/20/2007

eveloped by Cell Genesys, have demonstrated safe, efficient and long-lasting gene transfer into a variety of human cells including both dividing and non-dividing cells such as nerve, liver, muscle and bone marrow stem cells. Lentiviral vectors, which are more efficient at targeting non-dividing cells than traditional retroviral vectors, have a larger gene delivery capacity than certain other gene delivery vectors and therefore hold the potential to be used to deliver a wider range of therapeutic genes.

About Cell Genesys

Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms -- GVAX(TM) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys is headquartered in South San Francisco, CA and has its principal manufacturing operation in Hayward, CA. For additional information, please visit the company's website at http://www.cellgenesys.com .

About Lentigen Corporation

Lentigen Corporation is a privately owned biotechnology company focused on the development of lentiviral vectors using its proprietary gene delivery technology for a wide range of applications in biotechnology and medicine. Lentiviral vectors are highly adapted delivery vehicles that can transport genes or gene silencing sequences into cells with high efficiency and stability. Lentigen is positioning itself to become the leading company for the development of Lentiviral vector technology. For further information, visit http://www.lentigen.com .

About GBP Capital

GBP Capital i
'/>"/>

SOURCE Cell Genesys, Inc.; GBP IP, LLC
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cell Genesys to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Cell Genesys to Present at the BIO Investor Forum
3. Cell Genesys to Webcast Third Quarter 2007 Conference Call
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 With the accelerated aging ... health expenditure as well as the improved medical ... diagnostic reagent industry has been developing quickly, especially ... 2013, Chinese in vitro diagnostics market size reached ... in vitro diagnostic reagents. , Read complete ...
(Date:7/30/2014)... Vycom announces the addition of Thermax PVC to ... Mutual (FM) 4910 fire propagation and smoke generation criteria ... tools, fume hoods, furniture and cabinetry. These criteria reduce ... used in electronic chip manufacturing. , Flametec ... workability and superior aesthetics. It is available in a ...
(Date:7/30/2014)...  Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), is ... technologies are used to discover, develop, manufacture and ... bio-based chemical, biopharmaceutical and industrial enzyme industries, announced ... Vice President and Chief Financial Officer. Tom will ... technology operations for Dyadic and will succeed ...
(Date:7/30/2014)... July 30, 2014  AtheroNova Inc. (OTCBB: AHRO), ... development of compounds to safely regress atherosclerotic plaque ... that its partner, CardioNova, has accomplished first dosing ... with AtheroNova,s lead compound, AHRO-001.  This Phase 1b ... Phase 1 safety trial completed in February 2014, ...
Breaking Biology Technology:China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Vycom Announces Flametec® Thermax PVC (FM4910 Listed) For a Variety of Clean Room Applications with Excellent Workability and Aesthetics 2Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4
... 9 Boston Scientific,Corporation (NYSE: BSX ) ... has revised its Rating Outlook on the Company, ... long-term credit rating of,BB+., Fitch said the ... is making toward stabilizing its drug-eluting stent and ...
... Pressure,BioSciences, Inc. (Nasdaq: PBIO ) ("PBI") ... (PNNL), the Harvard School of,Public Health (HSPH), the ... Drug Administration (FDA) presented data generated through the,use ... last week,s,(June 1-5) American Society for Mass Spectrometry,s ...
... Inc. (Nasdaq:,NUVA), a medical device company focused on developing ... today,that Kevin O,Boyle, Executive Vice President and Chief Financial ... Annual Growth Stock,Conference at the Four Season Hotel, Chicago, ... A live Web cast of the presentation will ...
Cached Biology Technology:Boston Scientific Welcomes Revised Outlook From Fitch Ratings 2Boston Scientific Welcomes Revised Outlook From Fitch Ratings 3Four Independent Research Groups Present Data Generated by Pressure Cycling Technology (PCT) at the ASMS Conference on Mass Spectrometry and Allied Topics in Denver, CO 2Four Independent Research Groups Present Data Generated by Pressure Cycling Technology (PCT) at the ASMS Conference on Mass Spectrometry and Allied Topics in Denver, CO 3Four Independent Research Groups Present Data Generated by Pressure Cycling Technology (PCT) at the ASMS Conference on Mass Spectrometry and Allied Topics in Denver, CO 4NuVasive to Present at William Blair 28th Annual Growth Stock Conference 2NuVasive to Present at William Blair 28th Annual Growth Stock Conference 3
(Date:7/30/2014)... published new research from Bjorn Brembs, professor of neurogenetics ... with a proof-of-concept figure allowing readers and reviewers to ... This represents an important leap forward for scientific publishing, ... quality of a scholarly output. , Figure 3 in ... and their code to F1000Research , and the ...
(Date:7/30/2014)... therapies for spinal cord injury (SCI), traumatic brain injury ... great deal has been learned over the past 30 ... factors that regulate axon growth, but this large body ... therapeutics. Prof. Lemmon and his team from University of ... root causes, but a consensus is emerging that one ...
(Date:7/30/2014)... a paper published online today in the journal ... researchers Evan Kodra and Auroop Ganguly found that while ... variability in temperature extremes. For instance, while each year,s ... averages will also tend to fall within a wider ... are currently being observed. This means that even as ...
Breaking Biology News(10 mins):F1000Research brings static research figures to life 2Big data confirms climate extremes are here to stay 2
... 11, 2013 Elsevier, a world-leading provider of scientific, ... launch of Journal of Forensic Radiology and Imaging ... the International Society of Forensic Radiology and Imaging (ISFRI). ... of forensic radiology and imaging, JOFRI aims ...
... Discovery , the flagship journal of the American Association ... American research centres, presents significant results in treating cancer ... This marks the first time that the therapeutic effect ... Barcelona, 11 February 2013. A study led by Dr ...
... By thinking of cells as programmable robots, researchers at Rice ... tiny blood vessels that feed the brain and help people ... Amina Qutub and her colleagues simulate patterns of microvasculature cell ... their lab. Eventually, they want to develop the ability to ...
Cached Biology News:Elsevier announces the launch of a new journal: Journal of Forensic Radiology and Imaging 2First-in-man study demonstrates the therapeutic effect of RNAi gene silencing in cancer treatment 2First-in-man study demonstrates the therapeutic effect of RNAi gene silencing in cancer treatment 3Rice University lab show how blood vessels regroup after stroke 2Rice University lab show how blood vessels regroup after stroke 3
PC based system for superior chemifluorescent, chemiluminescent, fluorescent and colorimetric, microarray and microscope imaging and analysis....
Pendrin (H-195)...
Request Info...
Conveniently document gels, films and membranes with a high quality thermal printer. , Compact, footprint printer , Supplies 256 gray scale for high resolution, archive-quality thermal film prints...
Biology Products: